iBio, Inc. (IBIO)

iBio, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

iBio, Inc. (IBIO) is a Biotechnology company based in US with a market capitalization of $22.6M. Free cash flow was negative at -$15.3M. This page tracks IBIO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 16 employees · IPO Aug 19, 2008

Valuation

Valuation & price

$1.47as of May 17, 2026· -52.1% vs 52w high

P/E ratio

Latest-FY diluted EPS

1.52

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$3.07$1.82$0.57Jul 25Jan 26Jul 26
$0.5752-week range$3.07
Loading valuation history…

Fundamentals

Key fundamentals

$22.6M

Market cap

Revenue growth (YoY)

100.0%

Gross margin

-$15.3M

Free cash flow (USD)

-$5.1M

Net debt

Net cash position

174.1%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$948K$400K

Free cash flow by year

20162025

-$8.1M-$15.3M

Gross margin by year

20212025

38.3%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJul 17, 2026Filing

    Annual Meeting Scheduled

  • 8-K eventJul 1, 2026Filing

    Preclinical Data Announcement

  • 8-K eventMay 12, 2026Filing

    Clinical Trial Initiation

  • Quarterly reportMay 12, 2026Filing

    10-Q Filed

  • 8-K eventMay 8, 2026Filing

    Director Appointment

  • 8-K eventApr 17, 2026Filing

    Warrant Expiration Update

  • 8-K eventApr 8, 2026Filing

    Clinical Trial Initiation

Questions

Frequently asked questions

What is iBio, Inc.'s market cap?

iBio, Inc. (IBIO) has a market capitalization of $22.6M.

What is IBIO's P/E ratio?

A meaningful P/E ratio is not available for IBIO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is IBIO's price-to-book (P/B) ratio?

IBIO trades at 1.52 times book value per share.

Are insiders buying IBIO stock?

SEC Form 4 filings show no open-market insider buys at iBio, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.